Fulcrum Therapeutics (FULC) Expected to Announce Earnings on Wednesday

Key Points

• Fulcrum Therapeutics is set to report its Q3 2025 earnings on October 29, 2025, with analysts predicting an earnings per share (EPS) of ($0.29).
• The company's stock price recently increased to $9.34, with a 52-week range between $2.32 and $9.89 and a market capitalization of $505.20 million.
• Analyst ratings for Fulcrum Therapeutics vary, with a consensus rating of "Moderate Buy" and a price target averaging $11.20.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) is anticipated to post its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.29) per share for the quarter. Individuals may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded up $0.39 during mid-day trading on Friday, hitting $9.34. The company's stock had a trading volume of 111,382 shares, compared to its average volume of 555,980. Fulcrum Therapeutics has a 52-week low of $2.32 and a 52-week high of $9.89. The stock's fifty day simple moving average is $7.89 and its two-hundred day simple moving average is $6.72. The firm has a market capitalization of $505.20 million, a P/E ratio of -7.65 and a beta of 2.93.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. increased its stake in Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company's stock valued at $31,572,000 after purchasing an additional 1,589,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Fulcrum Therapeutics during the second quarter valued at $9,207,000. Invesco Ltd. increased its stake in Fulcrum Therapeutics by 448.4% during the second quarter. Invesco Ltd. now owns 470,333 shares of the company's stock valued at $3,236,000 after purchasing an additional 384,566 shares during the last quarter. American Century Companies Inc. increased its stake in Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company's stock valued at $911,000 after purchasing an additional 8,638 shares during the last quarter. Finally, Acuta Capital Partners LLC bought a new stake in Fulcrum Therapeutics during the second quarter valued at $410,000. Institutional investors own 89.83% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on FULC. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Fulcrum Therapeutics in a research note on Monday. Royal Bank Of Canada lifted their price objective on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a research note on Wednesday, July 30th. Leerink Partners set a $20.00 price objective on shares of Fulcrum Therapeutics and gave the company an "outperform" rating in a research note on Tuesday. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, September 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $11.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.